Adicet Bio, Inc.
NASDAQ:ACETBiotechnology
+$0.02 today
- Market cap
- $51.70M
- Beta
- 1.57
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$10.13
Volume 0.15M
Average 0.12M
Returns on capital
Adicet Bio, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-73.4%
avg -28.8%
ROIC
-70.2%
avg -33.1%
ROA
-60.7%
avg -31.3%
Analysis
ROA is currently the strongest return metric at -60.7% versus its period average of -31.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Chen Schor | Chief Executive Officer, President & Director | USD 953.67K | 54 | 55.00K | 0.59% |
Blake Aftab | Senior Vice President & Chief Scientific Officer | USD 731.12K | 45 | 55.00K | 0.59% |
Julie Maltzman | Chief Medical Officer | USD 622.2K | 58 | — | — |
Brian Nicholas Harvey | Chief Financial Officer | USD 611.14K | 65 | 43.36K | 0.46% |
Donald Healey | Chief Technology Officer | USD 606.34K | 64 | — | — |
Lloyd Klickstein | Interim Chief Medical Officer & Director | USD 44K | 69 | 18.30K | 0.20% |
Amy Locke | Chief Human Resource Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Oct 3, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 5, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$1.60M
Sells
4
$674,847.06
Net Transaction Value
+$929,087.07
Net buying
Most Active
ORBIMED ADVISORS LLC
4 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Apr 8, 26Apr 8, 2026 | ORBIMED ADVISORS LLC Indirect | Sell | $263.5K$263,512.32 |
| Apr 8, 26Apr 8, 2026 | ORBIMED ADVISORS LLC Indirect | Sell | $204.6K$204,569.67 |
| Apr 7, 26Apr 7, 2026 | ORBIMED ADVISORS LLC Indirect | Sell | $191.5K$191,453.07 |
| Apr 7, 26Apr 7, 2026 | ORBIMED ADVISORS LLC Indirect | Sell | $15.3K$15,312.00 |
| Feb 20, 26Feb 20, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Buy | $543.4K$543,439.77 |
| Feb 19, 26Feb 19, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Buy | $535.5K$535,472.28 |
| Feb 18, 26Feb 18, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Buy | $525K$525,022.08 |
Summary
Insiders reported 3 buys worth $1.60M and 4 sells worth $674,847.06 over the last 12 months. That adds up to net buying of $929,087.07. ORBIMED ADVISORS LLC was the most active insider with 4 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Adicet Bio, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ACET's management, answered from reported figures.
Who manages ACET?
Adicet Bio, Inc. (ACET) lists 7 active executives. The top listed executive is Chen Schor, Chief Executive Officer, President & Director.
Are ACET insiders buying or selling?
Recent insider activity shows net buying of $3.53M.
Continue the stock analysis
Jump to another research area for this company.